Clinical value of serum and tissue AGR2 for diagnosis and prognosis in epithelial ovarian cancer

To clarify the value of AGR2 for diagnosis and prognosis in epithelial ovarian cancer (EOC). Serum AGR2 from 203 subjects were detected by ELISA, while CA125 and HE4 were determined by enhanced chemiluminescence immunoassay. The diagnostic efficacy was assessed using receiver operating characteristi...

Full description

Saved in:
Bibliographic Details
Published inBiomarkers in medicine Vol. 17; no. 6; pp. 325 - 336
Main Authors Yan, Tianqing, Wang, Haozhe, Ma, Xiaolu, Cao, Jiazhen, Tong, Ying, Guo, Lin, Lu, Renquan
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.03.2023
Subjects
anterior gradient 2
CA125
diagnosis and prognosis
epithelial ovarian cancer
HE4
CA125
anterior gradient 2
epithelial ovarian cancer
HE4
diagnosis and prognosis
Online AccessGet full text

Cover

Abstract To clarify the value of AGR2 for diagnosis and prognosis in epithelial ovarian cancer (EOC). Serum AGR2 from 203 subjects were detected by ELISA, while CA125 and HE4 were determined by enhanced chemiluminescence immunoassay. The diagnostic efficacy was assessed using receiver operating characteristic curves. Tissue microarray was employed to compare tissue AGR2. Combined detection of AGR2, CA125 and HE4 improved the diagnostic specificity in the discrimination of EOC from healthy controls. Serum AGR2 was significantly higher, while CA125 and HE4 were significantly lower in EOC patients post-operatively. Low AGR2 expression may predict poorer prognosis. Incorporation of AGR2 improved the specificity of CA125 and HE4 in EOC diagnosis, and may act as a tumor suppressor whose low expression in EOC patients predicted poorer outcomes.
AbstractList To clarify the value of AGR2 for diagnosis and prognosis in epithelial ovarian cancer (EOC). Serum AGR2 from 203 subjects were detected by ELISA, while CA125 and HE4 were determined by enhanced chemiluminescence immunoassay. The diagnostic efficacy was assessed using receiver operating characteristic curves. Tissue microarray was employed to compare tissue AGR2. Combined detection of AGR2, CA125 and HE4 improved the diagnostic specificity in the discrimination of EOC from healthy controls. Serum AGR2 was significantly higher, while CA125 and HE4 were significantly lower in EOC patients post-operatively. Low AGR2 expression may predict poorer prognosis. Incorporation of AGR2 improved the specificity of CA125 and HE4 in EOC diagnosis, and may act as a tumor suppressor whose low expression in EOC patients predicted poorer outcomes.
Author Ma, Xiaolu
Yan, Tianqing
Cao, Jiazhen
Lu, Renquan
Wang, Haozhe
Tong, Ying
Guo, Lin
AuthorAffiliation 3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
2Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai, 200032, China
1Qingdao Institute, Fudan University, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Qingdao, 266500, China
AuthorAffiliation_xml – name: 2Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai, 200032, China
– name: 3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
– name: 1Qingdao Institute, Fudan University, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Qingdao, 266500, China
Author_xml – sequence: 1
  givenname: Tianqing
  orcidid: 0000-0003-3410-0395
  surname: Yan
  fullname: Yan, Tianqing
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
– sequence: 2
  givenname: Haozhe
  surname: Wang
  fullname: Wang, Haozhe
  organization: Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai, 200032, China
– sequence: 3
  givenname: Xiaolu
  surname: Ma
  fullname: Ma, Xiaolu
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
– sequence: 4
  givenname: Jiazhen
  surname: Cao
  fullname: Cao, Jiazhen
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
– sequence: 5
  givenname: Ying
  surname: Tong
  fullname: Tong, Ying
  organization: Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, No. 270, Dong'An Road, Xuhui District, Shanghai, 200032, China
– sequence: 6
  givenname: Lin
  surname: Guo
  fullname: Guo, Lin
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
– sequence: 7
  givenname: Renquan
  orcidid: 0000-0003-3291-5742
  surname: Lu
  fullname: Lu, Renquan
  organization: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37284743$$D View this record in MEDLINE/PubMed
BookMark eNp1kD1PwzAQhi1URD9gZEUeWQL-iO1krCooSJWQEMzGdS5glDjFTirx73Fp6cbkO9_jV-dnika-84DQJSU3jFF1u27bjBHGM0JVcYImVAmWEa7o6FhLPkbTGD8JEUpJdobGXLEiVzmfoLdF47yzpsFb0wyAuxpHCEOLja9w72JMd_PlM8N1F3DlzLvvoou_003oDp3zGDau_4DGpaBua4IzHlvjLYRzdFqbJsLF4Zyh1_u7l8VDtnpaPi7mq8zynPeZKQu5thVXwAShUlRlJdPiZS6lYFYUNSe1pTQ3yhQC6lKAlXkFdG1sCSAYn6HrfW5a62uA2OvWRQtNYzx0Q9SsYFwQIlmZ0GyP2tDFGKDWm-BaE741JXonVSepeidV76Qm_uoQPaxbqI70n8UElHugHvohQLQO0tf1vksvnHUe_gn_AdkUh_c
CitedBy_id crossref_primary_10_3390_biom14070743
crossref_primary_10_1016_j_ncrna_2024_06_002
crossref_primary_10_1155_2023_3970444
crossref_primary_10_1186_s11658_024_00601_w
Cites_doi 10.1016/S0140-6736(18)32552-2
10.1186/s13048-017-0315-6
10.1002/cncr.34496
10.1016/j.bpobgyn.2020.02.010
10.1016/j.canlet.2017.10.024
10.1097/CM9.0000000000002108
10.3390/ijerph191912057
10.1016/j.biopha.2016.09.087
10.4161/cbt.9.9.11610
10.3322/caac.21708
10.1016/j.heliyon.2020.e05000
10.1007/s00428-012-1273-4
10.1038/onc.2016.459
10.1186/s12885-015-1658-2
10.1371/journal.pone.0122106
10.1111/j.1742-4658.2010.07793.x
10.1186/1476-4598-9-186
10.1186/bcr3408
10.1038/modpathol.2012.238
10.1016/j.ebiom.2018.12.054
10.18632/oncotarget.7400
10.1016/j.canlet.2010.12.023
10.1016/j.humpath.2008.08.003
10.3390/cancers14122885
10.1158/1055-9965.EPI-18-0203
10.1186/s13048-019-0503-7
10.1016/0092-8674(89)90413-3
10.3390/cancers14163888
10.3858/emm.2011.43.2.011
10.1097/PAT.0b013e32835bd561
10.3343/alm.2020.40.2.114
10.1016/j.lfs.2020.117396
10.1530/ERC-19-0095
10.1001/jama.2011.766
10.3390/proteomes10020016
10.1530/ERC-11-0329
10.3390/curroncol29040220
10.1098/rsob.220068
ContentType Journal Article
Copyright 2023 Future Medicine Ltd
Copyright_xml – notice: 2023 Future Medicine Ltd
DBID NPM
AAYXX
CITATION
7X8
DOI 10.2217/bmm-2023-0178
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1752-0371
EndPage 336
ExternalDocumentID 10_2217_bmm_2023_0178
37284743
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: NSF-81772774, NSF-81772808
GroupedDBID ---
0R~
23N
4.4
53G
5GY
6J9
70G
7X7
8C1
ABJNI
ACGFO
ACGFS
ACPRK
ACWKX
ADBBV
AENEX
AFFYO
AHMBA
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
CS3
DU5
EBS
EHMNL
F5P
HCIFZ
HZ~
IAO
IEA
IHR
M1P
MV1
NTCAX
O9-
RFM
TFL
3V.
88E
8AO
8FE
8FH
8FI
8FJ
ABUWG
AFKRA
BHPHI
BPHCQ
BVXVI
CCPQU
EJD
FYUFA
HMCUK
ITC
LK8
M7P
NPM
OVD
PQQKQ
PROAC
PSQYO
TEORI
UKHRP
AAYXX
ALIPV
CITATION
H13
M4Z
RPM
TDBHL
TFMDE
TMEDX
7X8
ID FETCH-LOGICAL-c343t-a986bcd37e250165d9d6363946652c58f30fc114a7a85ef95ec64de1bac9ee523
ISSN 1752-0363
IngestDate Fri Aug 16 21:36:49 EDT 2024
Thu Sep 12 21:13:45 EDT 2024
Thu May 23 23:30:29 EDT 2024
Fri May 10 00:16:07 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords CA125
anterior gradient 2
epithelial ovarian cancer
HE4
diagnosis and prognosis
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c343t-a986bcd37e250165d9d6363946652c58f30fc114a7a85ef95ec64de1bac9ee523
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3410-0395
0000-0003-3291-5742
PMID 37284743
PQID 2823500629
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2823500629
crossref_primary_10_2217_bmm_2023_0178
pubmed_primary_37284743
futurescience_futuremedicine_10_2217_bmm_2023_0178
PublicationCentury 2000
PublicationDate 2023-Mar
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-Mar
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biomarkers in medicine
PublicationTitleAlternate Biomark Med
PublicationYear 2023
Publisher Future Medicine Ltd
Publisher_xml – name: Future Medicine Ltd
References e_1_3_5_29_1
e_1_3_5_28_1
e_1_3_5_27_1
e_1_3_5_26_1
e_1_3_5_25_1
e_1_3_5_24_1
e_1_3_5_23_1
e_1_3_5_22_1
e_1_3_5_3_1
e_1_3_5_40_1
e_1_3_5_9_1
e_1_3_5_21_1
e_1_3_5_8_1
e_1_3_5_20_1
e_1_3_5_5_1
e_1_3_5_4_1
e_1_3_5_7_1
e_1_3_5_6_1
e_1_3_5_18_1
e_1_3_5_17_1
e_1_3_5_39_1
e_1_3_5_16_1
e_1_3_5_38_1
e_1_3_5_15_1
e_1_3_5_37_1
e_1_3_5_13_1
e_1_3_5_14_1
e_1_3_5_36_1
e_1_3_5_35_1
e_1_3_5_11_1
e_1_3_5_34_1
e_1_3_5_12_1
e_1_3_5_33_1
e_1_3_5_19_1
e_1_3_5_32_1
e_1_3_5_10_1
e_1_3_5_31_1
e_1_3_5_30_1
References_xml – ident: e_1_3_5_8_1
  doi: 10.1016/S0140-6736(18)32552-2
– ident: e_1_3_5_13_1
  doi: 10.1186/s13048-017-0315-6
– ident: e_1_3_5_21_1
  doi: 10.1002/cncr.34496
– ident: e_1_3_5_5_1
  doi: 10.1016/j.bpobgyn.2020.02.010
– ident: e_1_3_5_26_1
  doi: 10.1016/j.canlet.2017.10.024
– ident: e_1_3_5_4_1
  doi: 10.1097/CM9.0000000000002108
– ident: e_1_3_5_7_1
  doi: 10.3390/ijerph191912057
– ident: e_1_3_5_16_1
  doi: 10.1016/j.biopha.2016.09.087
– ident: e_1_3_5_17_1
  doi: 10.4161/cbt.9.9.11610
– ident: e_1_3_5_3_1
  doi: 10.3322/caac.21708
– ident: e_1_3_5_40_1
  doi: 10.1016/j.heliyon.2020.e05000
– ident: e_1_3_5_39_1
  doi: 10.1007/s00428-012-1273-4
– ident: e_1_3_5_24_1
  doi: 10.1038/onc.2016.459
– ident: e_1_3_5_25_1
  doi: 10.1186/s12885-015-1658-2
– ident: e_1_3_5_36_1
  doi: 10.1371/journal.pone.0122106
– ident: e_1_3_5_34_1
  doi: 10.1111/j.1742-4658.2010.07793.x
– ident: e_1_3_5_20_1
  doi: 10.1186/1476-4598-9-186
– ident: e_1_3_5_27_1
  doi: 10.1186/bcr3408
– ident: e_1_3_5_28_1
  doi: 10.1038/modpathol.2012.238
– ident: e_1_3_5_14_1
  doi: 10.1016/j.ebiom.2018.12.054
– ident: e_1_3_5_31_1
  doi: 10.18632/oncotarget.7400
– ident: e_1_3_5_23_1
  doi: 10.1016/j.canlet.2010.12.023
– ident: e_1_3_5_30_1
  doi: 10.1016/j.humpath.2008.08.003
– ident: e_1_3_5_9_1
  doi: 10.3390/cancers14122885
– ident: e_1_3_5_12_1
  doi: 10.1158/1055-9965.EPI-18-0203
– ident: e_1_3_5_33_1
  doi: 10.1186/s13048-019-0503-7
– ident: e_1_3_5_22_1
  doi: 10.1016/0092-8674(89)90413-3
– ident: e_1_3_5_11_1
  doi: 10.3390/cancers14163888
– ident: e_1_3_5_37_1
  doi: 10.3858/emm.2011.43.2.011
– ident: e_1_3_5_38_1
  doi: 10.1097/PAT.0b013e32835bd561
– ident: e_1_3_5_10_1
  doi: 10.3343/alm.2020.40.2.114
– ident: e_1_3_5_29_1
  doi: 10.1016/j.lfs.2020.117396
– ident: e_1_3_5_19_1
  doi: 10.1530/ERC-19-0095
– ident: e_1_3_5_6_1
  doi: 10.1001/jama.2011.766
– ident: e_1_3_5_18_1
  doi: 10.3390/proteomes10020016
– ident: e_1_3_5_32_1
  doi: 10.1530/ERC-11-0329
– ident: e_1_3_5_15_1
  doi: 10.3390/curroncol29040220
– ident: e_1_3_5_35_1
  doi: 10.1098/rsob.220068
SSID ssj0057762
Score 2.3586657
Snippet To clarify the value of AGR2 for diagnosis and prognosis in epithelial ovarian cancer (EOC). Serum AGR2 from 203 subjects were detected by ELISA, while CA125...
SourceID proquest
crossref
pubmed
futurescience
SourceType Aggregation Database
Index Database
Publisher
StartPage 325
SubjectTerms anterior gradient 2
CA125
diagnosis and prognosis
epithelial ovarian cancer
HE4
Title Clinical value of serum and tissue AGR2 for diagnosis and prognosis in epithelial ovarian cancer
URI http://dx.doi.org/10.2217/bmm-2023-0178
https://www.ncbi.nlm.nih.gov/pubmed/37284743
https://search.proquest.com/docview/2823500629
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3dS90wFMDDdC-CjI3pdqcbGYgvI2qTpmkfRbbJYHsQBd-6NE3hwm57ufb64F_vOTn9WEVh86W0adLcm1-anuTknMPYgTOmUkppgUGsBIySWlgXRaLyiTE68bFO0d7556_k_Cr-ca2vx-CXwbqkLY7c3aN2Jc-hCmnAFa1k_4Ps8FBIgHPgC0cgDMd_YnzWmzWiy-4w-Ydq1xT0og0t-uX0-4UMWwlL2lM3v-lcAzTdFboMWaJhxh9cO29uYe4Mr7zDzrCaaHznzQK38qxCkYlKvls0kGrcNUWxf4O_EtIFoTA77iDCMdBoKVC_S5-Iv9MoWsrDUVfK4KqpWCwE1RVRVJ4HjqxhuoE5c8iXY74c822wl9Jk2vTrLPQN1caEULDDTyHvqFj8eFLNRJrYJjcsnejw9JQhiA6Xr9mrTubnpwTwDXvh67fsdw-PB3i8qXiAxwEPJ3gc4XGAxwd44e4Aj89rPsLjHTxO8HbY1bevl2fnogt3IZyKVStsliaFK5XxIJZGiS6zMoG_jgEAtHQ6rdRJBa9RbI1Nta8y7V0Slz4qrMu811Ltss26qf17xlF7XKhUF5mxsTzxuGqljC0LH3kLcsuMHfbNli_Jq0n-KJ4Zk5NGzemq72RPFfrct3wOgxVqoGztm_VNDvN7pdFsN5uxd4RkqF8ZlJRi9eE5Ve6xrbGb77PNdrX2H0FabItPoWPdA_y1a3c
link.rule.ids 315,786,790,27957,27958
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+value+of+serum+and+tissue+AGR2+for+diagnosis+and+prognosis+in+epithelial+ovarian+cancer&rft.jtitle=Biomarkers+in+medicine&rft.date=2023-03-01&rft.pub=Future+Medicine+Ltd&rft.issn=1752-0363&rft.eissn=1752-0371&rft_id=info:doi/10.2217%2Fbmm-2023-0178&rft.externalDocID=10_2217_bmm_2023_0178
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-0363&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-0363&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-0363&client=summon